. 2017 Jan 5;35(2):248–254. doi: 10.1016/j.vaccine.2016.11.085

Table 2.

Group mean microscopic lesions and presence and amount of PCV2 antigen at 21 days post PCV2 challenge.

Group	Lymphoid tissues		Lungs
Group	Overall lymphoid depletion score^a	PCV2 antigen in lymph nodes^b	Interstitial pneumonia^c	PCV2 antigen in lung tissues^b
NEG	0.1 ± 0.1^A^,^d	0/10 (0.0 ± 0.0)^A	0.4 ± 0.2^A	0/10 (0.0 ± 0.0)
VAC	0.3 ± 0.2^A,B	0/9 (0.0 ± 0.0)^A	0.6 ± 0.2^A,B	0/9 (0.0 ± 0.0)
VAC + CHAL	1.6 ± 0.7^B	1/9 (0.1 ± 0.1)^A	0.7 ± 0.3^A,B	1/9 (0.1 ± 0.1)
CHAL	2.5 ± 0.7^B	6/10 (0.9 ± 0.3)^B	1.4 ± 0.3^B	4/10 (0.1 ± 0.1)

Overall lymphoid depletion score ranging from 0 = normal to 9 = severe.

Determined by immunohistochemistry ranging from 0 = absent to 3 = abundant antigen.

Interstitial pneumonia score ranging from 0 = normal to 6 = severe.

Data presented as group mean ± SEM or as prevalence (group mean ± SEM). Groups connected by different superscripts within a column have significantly (P < 0.05) different group means.